104 results
Thumbnail

D3.364 - Effect of Omalizumab on Inflammatory and Immune Biomarkers in Mast Cell-Mediated Angioedema

Thumbnail

D3.97 - Postoperative Anti-IgE Therapy for Chronic Rhinosinusitis with Nasal Polyps and Asthma: Efficacy and Prognostic Factors

Thumbnail

- D3.99 - Early Real-World Outcomes of Tezepelumab in Severe Asthma Patients Unresponsive to Prior Biologics

Thumbnail

D3.138 - Asthma remission in EGPA patients: applicability and concordance of the main international guidelines

Thumbnail

D3.23 - Descriptive and Comparative Analysis of Clinical and Endoscopic Characteristics and Treatment Response in Adult Patients with Eosinophilic Esophagitis (EoE): a preliminary experience of an Italian centre

Thumbnail

D3.26 - Anaphylaxis associated with biosimilar Tocilizumab: in vitro and in vivo diagnosis

Thumbnail

D3.274 - Succesful Omalizumab Desensitization in Two Children with Severe Allergic Asthma and Cronic Spontaneous Urticaria

Thumbnail

D3.28 - Comparative Efficacy and Safety of Omalizumab Intended copy Biosimilar vs. Biologic in Chronic Spontaneous Urticaria

Thumbnail

D3.283 - Taming the Unpredictable: Omalizumab’s Role in Idiopathic anaphylaxis and chronic spontaneous urticaria

Thumbnail

D3.29 - Detailed Clinical Characterization of a Large Cohort of Chronic Spontaneous Urticaria Patients

Thumbnail

D3.33 - Severe Eosinophilic Esophagitis: the Key Role of Biologics in Disease Management

Thumbnail

D3.358 - The impact of limited access to On-Demand Treatment for Hereditary Angioedema on Quality of life: a comparison between two income settings

Thumbnail

D3.359 - Study of olfaction in patients with chronic rhinosinusitis with nasal polyposis undergoing Mepolizumab treatment

Thumbnail

D3.362 - Use and safety of canakinumab during pregnancy

Thumbnail

D3.363 - Vitamin D3 deficiency promotes epithelial-to-mesenchymal transition and thus favours pulmonary fibrosis development in the murine model of hypersensitivity pneumonitis

Thumbnail

D3.365 - The role of anosmia in predicting biologic responsiveness for Chronic Rhinosinusitis with Nasal Polyposis

Thumbnail

D3.366 - Exploring potential predictive factors for time to response to Omalizumab treatment in a Romanian subset of patients with Chronic Spontaneous Urticaria

Thumbnail

D3.367 - Mental health, sexual functionality, quality of life, and patient experiences with chronic rhinosinusitis with nasal polyps at UNIMEQ-ORL in Bogotá, Colombia, 2022-2024: a mixed-methods study

Thumbnail

D3.368 - Analysis of discontinuation of omalizumab in patients with chronic spontaneous and/or inducible urticaria in a tertiary hospital in one year

Thumbnail

D3.390 - Rationale and Design for ALPHA-ORBIT: a phase 3 trial of navenibart, a monoclonal antibody inhibitor of plasma kallikrein for participants with hereditary angioedema (HAE)